CN101172968B - 2-propyl-4 methyl-6-(tolimidazole-2group) benzoglioxaline salt and method for producing the same - Google Patents

2-propyl-4 methyl-6-(tolimidazole-2group) benzoglioxaline salt and method for producing the same Download PDF

Info

Publication number
CN101172968B
CN101172968B CN200610117824A CN200610117824A CN101172968B CN 101172968 B CN101172968 B CN 101172968B CN 200610117824 A CN200610117824 A CN 200610117824A CN 200610117824 A CN200610117824 A CN 200610117824A CN 101172968 B CN101172968 B CN 101172968B
Authority
CN
China
Prior art keywords
methyl
propyl
tolimidazole
benzoglioxaline salt
add
Prior art date
Application number
CN200610117824A
Other languages
Chinese (zh)
Other versions
CN101172968A (en
Inventor
屠勇军
黄正良
程荣德
Original Assignee
浙江天宇药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江天宇药业有限公司 filed Critical 浙江天宇药业有限公司
Priority to CN200610117824A priority Critical patent/CN101172968B/en
Publication of CN101172968A publication Critical patent/CN101172968A/en
Application granted granted Critical
Publication of CN101172968B publication Critical patent/CN101172968B/en

Links

Abstract

The invention relates to an intermediate 2-n-propyl-4 methyl-6-(methyl benzimidazole-2- radical) benzimidazole salt for high blood pressure resistance medicine that is telmisartan and the preparation method thereof. The intermediate has no any reports in the literature. The invention has the advantages of easy control of the preparation reaction condition, easy getting of raw material, and being suitable for mass production. The intermediate can be used for preparing the telmisartan.

Description

2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt and preparation method thereof

Technical field

The present invention relates to field of medicine preparing technology, be specifically related to prepare intermediate 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt of telmisartan and preparation method thereof.

Background technology:

Along with the research of medical sci-tech antagonism hypertension, antihypertensive drug of new generation comes out gradually, and is widely used in clinical.Non-peptide class vasotonia II acceptor inhibitor, promptly sartans has become antihypertensive generation new drug, and such medicine has remarkable curative effect and good tolerability, and to treatment primary and secondary hypertension, and congestive heart failure has effect preferably.Preparation for sartans has also become the problem of paying close attention to.Telmisartan is a kind of of sartans, and this medical instrument has advantages such as bioavailability height, long half time.About the existing various kinds of document report of the preparation method of telmisartan.J.Med.Chem. (1993), 36 (25), 4040-51 and International Patent Application WO 0063158, CN1412183A, CN1344712A, CN1768044A have announced the synthetic method J.Med.Chem. (1993) of telmisartan, 36 (25), 4040-51 and International Patent Application WO 0063158, US6770762 discloses preparation of 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline and process for purification.Wherein 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline is the intermediate of preparation telmisartan, (but some defectives are arranged with this synthesis technique of making intermediate, yield and purity were not ideal enough when two imidazoles were synthetic in the former technology, next step N alkylated reaction is complete inadequately simultaneously, cause purifying telmisartan difficulty), it is synthetic that the alternative former 2-n-propyl of 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline carries out telmisartan, also help next step N alkylated reaction simultaneously, and do not influence the synthetic and quality of telmisartan.The telmisartan yield that obtains is higher, easier purifying.

Summary of the invention:

Inventor's technical problem to be solved is to overcome above-mentioned weak point, the intermediate of the preparation telmisartan that research and design is new.

The invention provides a kind of preparation telmisartan intermediate 2-n-propyl-4 methyl-6-(tolimidazole 2-yl) benzoglioxaline salt, its structural formula is as follows:

R is N a +, K +Deng metal ion.

(be dissolved in alcohol (as methyl alcohol. ethanol etc.), water insoluble.

Be hydrolyzed to 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline under the non-alkaline condition.2-n-propyl-4 methyl-6-(methylbenzene, and imidazoles-2-yl) benzoglioxaline salt need could be stablized with highly basic (as: NaOH, KOH etc.) symbiosis.2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt can be applicable to the synthetic of telmisartan.

2-n-propyl of the present invention-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt (mp:198-201 ℃ .) makes by following method:

R is Na, metal ions such as K, or ROH is sodium methylate, sodium ethylate, potassium tert.-butoxide etc.

Temperature of reaction is 20 ℃-100 ℃

The inventive method comprises the following steps:

1,2-n-propyl-4 methyl-6-carboxy benzimidazole and N-methyl-o-phenylenediamine (or its hydrochloride) are that solvent was 100 ℃-160 ℃ reactions 8~20 hours with PPA (polyphosphoric acid) or PPA and methylsulfonic acid or methylsulfonic acid and P2O5, wherein 2-n-propyl-4 methyl-6-carboxy benzimidazole and N-methyl-o-phenylenediamine (or its hydrochloride) are 1: 1.0~1.3: 3~8 with the mol ratio of solvent, generate 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline.Add an amount of distilled water then, add hydrochloric acid to PH=1~2, activated carbon decolorizing is 12~14 regulating PH with mineral alkali ROH or organic bases repeatedly.React 1~5 hour after-filtration under the room temperature, get product 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt.

2, with gained intermediate 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt dissolving crude product in alcohol (methyl alcohol, ethanol, Virahol etc.) reflux 5-10 minute, filtered while hot adds an amount of ROH solution, cooling, crystallization.Both can obtain 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt.ROH is NaOH, inorganic strong alkali or sodium methylates such as KOH, sodium ethylate, organic alkalis such as potassium tert.-butoxide.

The present invention with the reaction of 2-n-propyl-4 methyl-6-carboxy benzimidazole and N-methyl-o-phenylenediamine (or its hydrochloride) after, in treating processes, add excessive alkali (as organic alkalis such as inorganic strong alkali such as NaOH, KOH or sodium methylate, sodium ethylate, potassium tert.-butoxides) and obtain this compound.This compound must with the ROH symbiosis, could keep the stability of this compound, and the ROH needed acid binding agent of next step N alkylated reaction just.

Use intermediate 2-n-propyl of the present invention-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt and 4-brooethyl-2-carboxyl ester biphenyl) the prepared in reaction telmisartan, have following advantage:

1, same raw material, the yield that the inventive method obtains new intermediate is high by 5~10%.

2, easier purifying after processing obtains new intermediate.

3, this intermediate is used for the synthetic of telmisartan, can also reduce next step reaction base consumption.

4, simple to operate, be fit to scale operation.

Embodiment:

Below each example further specify the present invention, but do not impose any restrictions.

Example 1

1, with 100gPPA; 21.8g (0.1mol) 2-n-propyl-4-methyl-6-carboxy benzimidazole and 21.5gN-methyl-o-phenylenediamine add in the reaction flask; under the N2 protection, feed intake; be heated to 100 ℃-160 ℃; reacted 8-20 hour; reduce to 70-80 ℃ and will react adding 200ml water; regulate PH=1~2 with hydrochloric acid, drop into gac 5-8%; 80 ℃ of filtrations in left and right sides 5-10 minute; reaction repeatedly, will regulate PH with NaOH is 12-14, stoichiometric number hour; filter, get intermediate crude product 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline sodium salt.

2, put into 200 milliliters of ethanol with previous step product 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline sodium salt crude product is molten, heating for dissolving, be cooled to room temperature, add 400 milliliters of 1N NaOH, separate out compound 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline sodium salt.50-80 ℃ of vacuum-drying.

3, previous step product 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline sodium salt is dropped into 200 milliliters of dimethyl sulfoxide (DMSO), stir, at room temperature add 4-brooethyl-diphenyl-2-carboxylic acid methyl esters 33.55 grams, stirred 14 hours, with dichloromethane extraction (200,100,100), evaporated under reduced pressure adds 300 ml methanol and 10% potassium hydroxide (240 milliliters 0.6mol) mix backflow 6 hours, cooling, with 80 milliliters of washed with dichloromethane, transfer to PH=6 with glacial acetic acid, separate out a large amount of white wadding precipitations, filter, whitely dry for rice crude product 49.6 grams, in crude product, add 100 milliliters of reflux of chloroform, decolorizing with activated carbon, crystallization, filter, 80 ℃ of vacuum-dryings get white pure product telmisartan (HLPC>99.0%) 41 grams, refining yield 82%.mp?261~263℃; 1H-NMR(d 6-DMSO)δ1.05t,3H),1.83(m,2H),2.71(s,3H),2.94(t,2H),3.81(s,3H),5.57(s,2H),7.16-7.83(m,14H).C 33H 33N 4O 2

Example 2 preparation telmisartans

1, with 100gPPA; 21.8g (0.1) 2-n-propyl-4 methyl-6-carboxy benzimidazole and 21.5gN-methyl-o-phenylenediamine add in the reaction flask; under the N2 protection, feed intake; be heated to 100 ℃-160 ℃; reacted 8-20 hour; reduce to 70-80 ℃ and will react adding 200ml water; regulate PH=1~2 with hydrochloric acid, drop into gac 5-8%; 80 ℃ of filtrations in left and right sides 5-10 minute; reaction repeatedly, will regulate PH with KOH is 12-14, stoichiometric number hour; filter, get intermediate crude product 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline sylvite.

2, previous step product 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline sylvite crude product is put into 200 milliliters of ethanol, heating for dissolving, be cooled to room temperature, add 400 milliliters of 1N KOH, separate out compound 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline sylvite.50-80 ℃ of vacuum-drying.

3,2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline sylvite and 27.2 gram 4-brooethyl-2-cyanobiphenyls with the previous step preparation, 10.4 gram triethylamine and DMF (DMA, methylene dichloride, ethylene dichloride) mixes, 35-40 degree reaction 5-10 hour, TLC pours reaction solution in frozen water 600 grams into after detecting no raw material, ethyl acetate extraction (300ml*3) merges organic phase, washing (300ml*2), dry, precipitation adds petroleum ether and stirring to solid again and separates out, and gets crude product 45.6 grams.

4, solid 45.6 grams with previous step add 200ml ethylene glycol, 150ml water, 12 gram sodium hydroxide, back flow reaction 10 hours, after TLC detects no raw material, be cooled to room temperature, transferring PH with hydrochloric acid is 5~6, has solid to separate out, filter, washing, the telmisartan crude product, the DMF recrystallization gets the 44.5 gram pure product of telmisartan (HLPC>99.0%) mp261~263 ℃. 1H-NMR(d 6-DMSO)δ1.05t,3H),1.83(m,2H),2.71(s,3H),2.94(t,2H),3.81(s,3H),5.57(s,2H),7.16-7.83(m,14H).C 33H 33N 4O 2

Example 3

1; with 100gPPA; 21.8g (0.1) 2-n-propyl-4 methyl-6-carboxy benzimidazole and 21.5gN-methyl-o-phenylenediamine add in the reaction flask; under the N2 protection, feed intake; be heated to 100 ℃-160 ℃; reacted 8-20 hour, and reduced to 70-80 ℃ and will react adding 200ml water, regulate pH=1~2 with hydrochloric acid; drop into gac 5-8%;, 80 ℃ of filtrations in left and right sides 5-10 minute, reactions repeatedly; to regulate PH with NaOH is 12~14; stoichiometric number hour filters, intermediate crude product 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline sodium salt.

2, previous step product 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline sodium salt crude product is put into 200 milliliters of Virahols, heating for dissolving, add activated carbon 2 grams, filtered while hot, add 200 ml waters in the filtrate, be cooled to room temperature, separate out compound 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline, filter, 80 degree vacuum-dryings get pure product 26 gram (HLPC>99.5%) .mp:193-195 ℃ of 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline.

Claims (3)

1. 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt is characterized in that it has following array structure:
R is N a +Or K +Metal ion; Be dissolved in alcohol, water insoluble; Under non-alkaline condition, be hydrolyzed to 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline.
2. the preparation method of the described 2-n-propyl of claim 1-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt is characterized in that this method comprises the following steps:
1) 2-n-propyl-4 methyl-6-carboxy benzimidazole and N-methyl-o-phenylenediamine or its hydrochloride are with polyphosphoric acid or polyphosphoric acid and methylsulfonic acid or methylsulfonic acid and P 2O 5Be solvent, wherein the mol ratio of 2-n-propyl-4 methyl-6-carboxy benzimidazole and N-methyl-o-phenylenediamine or its hydrochloride and solvent is 1: 1.0~1.3: 3~8; 100 ℃-160 ℃ reactions 8-20 hour, generate 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglyoxaline, add an amount of distilled water then, add hydrochloric acid to pH be 1~2, activated carbon decolorizing repeatedly, regulating pH with alkali again is 12~14, reacts 1~5 hour after-filtration, gets product 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt;
2) with gained intermediate 2-n-propyl 4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt dissolving crude product in methyl alcohol, ethanol or Virahol, reflux 5-10 minute, filtered while hot, add NaOH or KOH, cooling, crystallization is filtered, and obtains 2-n-propyl-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt; The add-on of described NaOH or KOH and 2-n-propyl 4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt is 1-10: 1 mol ratio.
3. according to the preparation method of the described 2-n-propyl of claim 2-4 methyl-6-(tolimidazole-2-yl) benzoglioxaline salt, it is characterized in that this method steps 1) described alkali is NaOH, KOH, sodium methylate, sodium ethylate or potassium tert.-butoxide.
CN200610117824A 2006-11-01 2006-11-01 2-propyl-4 methyl-6-(tolimidazole-2group) benzoglioxaline salt and method for producing the same CN101172968B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200610117824A CN101172968B (en) 2006-11-01 2006-11-01 2-propyl-4 methyl-6-(tolimidazole-2group) benzoglioxaline salt and method for producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200610117824A CN101172968B (en) 2006-11-01 2006-11-01 2-propyl-4 methyl-6-(tolimidazole-2group) benzoglioxaline salt and method for producing the same

Publications (2)

Publication Number Publication Date
CN101172968A CN101172968A (en) 2008-05-07
CN101172968B true CN101172968B (en) 2010-05-12

Family

ID=39421745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200610117824A CN101172968B (en) 2006-11-01 2006-11-01 2-propyl-4 methyl-6-(tolimidazole-2group) benzoglioxaline salt and method for producing the same

Country Status (1)

Country Link
CN (1) CN101172968B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6210599B2 (en) * 2014-02-26 2017-10-11 株式会社トクヤマ Process for producing 4-methyl-6 (1-methylbenzimidazol-2-yl) -2-n-propyl-1H-benzimidazole
CN104974096B (en) * 2015-07-07 2019-02-01 威海迪素制药有限公司 A kind of preparation method of telmisartan intermediate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1412183A (en) * 2001-10-15 2003-04-23 中国科学院上海药物研究所 New preparation method of timixatan
CN1620437A (en) * 2002-01-18 2005-05-25 贝林格尔英格海姆法玛两合公司 Method for the production and purification of 1,7'-dimethyl-2'-propyl-2,5'-bi-1h-benzimidazole
WO2005108375A1 (en) * 2004-05-11 2005-11-17 Cipla Limited Process for the preparation of telmisartan
CN1768044A (en) * 2003-03-31 2006-05-03 贝林格尔·英格海姆国际有限公司 Process for manufacture of telmisartan

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1412183A (en) * 2001-10-15 2003-04-23 中国科学院上海药物研究所 New preparation method of timixatan
CN1620437A (en) * 2002-01-18 2005-05-25 贝林格尔英格海姆法玛两合公司 Method for the production and purification of 1,7'-dimethyl-2'-propyl-2,5'-bi-1h-benzimidazole
CN1768044A (en) * 2003-03-31 2006-05-03 贝林格尔·英格海姆国际有限公司 Process for manufacture of telmisartan
WO2005108375A1 (en) * 2004-05-11 2005-11-17 Cipla Limited Process for the preparation of telmisartan

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
常选妞等.替米沙坦的合成工艺改进.精细化工23 7.2006,23(7),661-663.
常选妞等.替米沙坦的合成工艺改进.精细化工23 7.2006,23(7),661-663. *

Also Published As

Publication number Publication date
CN101172968A (en) 2008-05-07

Similar Documents

Publication Publication Date Title
CA2651136C (en) Substituted thieno-fused pyrimidines as p13k inhibitors
ES2432647T3 (en) Procedure for the preparation of telmisartan
CN102633713B (en) Dabigatran etexilate intermediate, preparation method for same and method for preparing dabigatran etexilate
CN102190616B (en) A kind of deuterated synthesis of ω-diphenyl urea and the Method and process of production
CN101817833B (en) DPP-IV inhibitor
KR20070050967A (en) Hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-pteridinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl)benzamide, methods for the production thereof, and use thereof as medicaments
TWI430999B (en) Process for the synthesis of organic compounds
CN104447743B (en) The preparation method of Pa Boxini
JP6267213B2 (en) Improved process for preparing 5- (2,6-di-4-morpholinyl-4-pyrimidinyl) -4-trifluoromethylpyridin-2-amine
CN101153012B (en) Novel method of producing dronedarone key intermediate
AU2012331547B2 (en) Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof
CN101657462B (en) The preparation method and intermediates of capecitabine
CN104230777A (en) Synthetic method of oxiracetam
KR101420892B1 (en) Process for the preparation of Imatinib and intermediates thereof
CN100451015C (en) Preparing method of imatinib
CN103755688B (en) A kind of Ah method is for the preparation method of Buddhist nun's compound
CN103342704B (en) A kind of preparation method of antithrombotic reagent Eliquis
CN103965114B (en) Deuterated phenyl amino pyrimidine compounds and comprise the pharmaceutical composition of this compound
CN102675297B (en) Preparation method of Lapatinib
EP2550269A1 (en) Process and intermediates for preparing lapatinib
EP0051829B1 (en) N-substituted omega-(2-oxo-4-imidazolin-1-yl) alcanoic acids, salts and esters thereof, process for producing the same and these active agents containing pharmaceutical compounds
CN100548968C (en) A kind of method for preparing 2-to octyl group styroyl-2-amino-propanediol hydrochloride
CN105777710B (en) A kind of Ai Le replaces the synthetic method of Buddhist nun
CN102336705B (en) Method for preparing N-(3,5-dichloropyridyl-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzoyl amine
CN101983195A (en) Novel polymorphs and processes for their preparation

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
GR01 Patent grant
C14 Grant of patent or utility model
CP01 Change in the name or title of a patent holder

Address after: 318020 Huangyan economic and Technological Development Zone, Zhejiang, Taizhou

Patentee after: Zhejiang Tianyu Pharmaceutical Co., Ltd.

Address before: 318020 Huangyan economic and Technological Development Zone, Zhejiang, Taizhou

Patentee before: Zhejiang Tianyu Pharmaceutical Co., Ltd.

C56 Change in the name or address of the patentee
TR01 Transfer of patent right

Effective date of registration: 20130618

Address after: 224555 Jiangsu Province, Yancheng City Binhai County Binhuai town head Zeng Village (Yancheng City coastal chemical industry park)

Patentee after: Binhai Sanyong Medicine Industry and Chemistry Co., Ltd.

Address before: 318020 Huangyan economic and Technological Development Zone, Zhejiang, Taizhou

Patentee before: Zhejiang Tianyu Pharmaceutical Co., Ltd.

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 318020 TAIZHOU, ZHEJIANG PROVINCE TO: 224555 YANCHENG, JIANGSU PROVINCE

C41 Transfer of patent application or patent right or utility model
ASS Succession or assignment of patent right

Owner name: BINHAI SANYONG MEDICINE INDUSTRY AND CHEMISTRY CO.

Free format text: FORMER OWNER: ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.

Effective date: 20130618